In this randomized trial, among patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slowed the decline in the ...

In this randomized controlled trial, treatment with nerandomilast led to slower declines in forced vital capacity (FVC) in patients with progressive pulmonary fibrosis over 52 weeks 2. The occurrence ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Results come after positive results from a trial among people with idiopathic pulmomary disease.

Nerandomilast significantly reduces the decline in forced vital capacity in adults with progressive pulmonary fibrosis over 52 weeks, thereby slowing the progression of the condition.

Nerandomilast, Boehringer Ingelheim ’s investigational oral therapy, significantly slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis ...

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (ILD) with a progressive pulmonary fibrosis phenotype ...

Boehringer’s nerandomilast shows lung function benefit in phase 3 IPF and PPF trials The candidate is currently under review for both interstitial lung diseases in the EU and US Boehringer Ingelheim ...

Nerandomilast met the primary endpoint in 2 pivotal phase 3 trials, slowing lung function decline in patients with IPF and PPF.

Nerandomilast Demonstrates Statistically Significant FVC Preservation in IPF and PPF In both the FIBRONEER-IPF and FIBRONEER-ILD Phase III trials, nerandomilast achieved the primary endpoint by ...

Boehringer Ingelheim announced detailed findings from the phase III FIBRONEER-IPF and FIBRONEER-ILD trials. These studies evaluated nerandomilast, an investigational oral, preferential inhibitor of ...